Clearing a deep thigh vein clot during treatment of leg vein thrombosis
Tests clearing thigh vein clots in adults with deep vein thrombosis.
Key facts
- Who runs it
- RenJi Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 24 Jun 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Endovascular treatment with profunda femoris vein thrombosis clearance (Endovascular treatment with PFV-TC)
- Percutaneous mechanical thrombectomy without profunda femoris vein thrombosis clearance (PMT without PFV-TC)
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a new blood clot in the deep veins of the pelvis and upper thigh (acute iliofemoral DVT). They must be having treatment inside the vein with a device that quickly removes the clot.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- Acute iliofemoral DVT that involves the iliac vein, the common femoral vein and the start (orifice) of the deep thigh vein (PFV). It must be confirmed by ultrasound, CT venography or venography. No more than 14 days from first symptoms to treatment.
- Earlier treatment
- People must be getting endovascular treatment (treatment through the veins) with a rapid endovascular thrombus removal device.
Main reasons for not taking part
- Post-thrombotic syndrome already present in the leg to be treated, or an earlier DVT with symptoms in the same leg
- Severe pulmonary embolism (clot in the lung) with low oxygen or low blood pressure
- Severe kidney weakness with creatinine clearance < 30 ml/min, active bleeding, bleeding or clotting disorders, or severe liver weakness
- Past bleeding in or around the brain, or a brain blood vessel malformation or aneurysm
- Pregnancy, or another disease with an expected life span < 24 months
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥ 18 years and ≤ 85 years
- Diagnosed with acute iliofemoral DVT involving iliac vein, common femoral vein, and the proximal segment (orifice) of PFV (confirmed by preoperative ultrasound, CT venography, or pre-procedural venography)
- Time from symptom onset to endovascular treatment ≤ 14 days
- Patient receives endovascular treatment with rapid endovascular thrombus removal device
- Patient provides written informed consent
Who cannot take part
- Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb
- Concomitant severe pulmonary embolism with hemodynamic compromise, such as hypoxia or hypotension
- Intolerance to endovascular intervention due to concurrent acute systemic illness, severe dyspnea, or other contraindications
- Participation in another clinical trial of a drug or medical device within the past 1 month that may interfere with the present study
- Presence of pre-existing PTS in the limb scheduled for treatment, or a history of symptomatic DVT in the same limb
- Known allergy to heparin, low-molecular-weight heparin, contrast media, or other relevant agents
- Presence of active bleeding, severe hepatic insufficiency, bleeding diathesis, or other coagulation disorders
- History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm
- Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency) with an estimated life expectancy < 24 months
- Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min
- Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or thrombocytopenia (platelet count < 80,000/mL)
- Pregnancy
- Unwillingness to participate in this trial
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS). The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein. Profunda femoris vein thrombosis clearance (PFV-TC) may improve the patency of iliofemoral vein and reduce the occurrence of PTS.
The 2 groups in the trial
- Endovascular treatment with PFV-TC groupTreatment being tested
Endovascular treatment with PFV-TC group (experimental group)
Treatment: Endovascular treatment with profunda femoris vein thrombosis clearance (Endovascular treatment with PFV-TC)
- Endovascular treatment without PFV-TC groupExisting treatment, for comparison
Endovascular treatment without PFV-TC group (control group)
Treatment: Percutaneous mechanical thrombectomy without profunda femoris vein thrombosis clearance (PMT without PFV-TC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis: a Multicenter Randomized Controlled Study (The PROTECT Study)
- Plain-language title
- Clearing a deep thigh vein clot during treatment of leg vein thrombosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07622199, who can take part
- Record updated
- 13 October 2026